• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Study in Nature Medicine Finds Taking Centrum Silver Daily May Slow Biological Aging

    3/9/26 1:00:00 PM ET
    $HLN
    Package Goods/Cosmetics
    Consumer Discretionary
    Get the next $HLN alert in real time by email

    An analysis of the COSMOS randomized trial provides early evidence that taking a daily multivitamin may help support healthy aging at the cellular level

    A new ancillary study published in Nature Medicine shows that Centrum Silver may slow biological aging markers.

    The findings come from an analysis of data from a randomized clinical trial, the COcoa Supplement and Multivitamin Outcomes Study (COSMOS), designed to evaluate how daily multivitamin use may influence biological aging over time. Biological aging refers to how well the body is functioning at a cellular level and may add important information about health span than chronological age alone. Led by researchers at Mass General Brigham and Augusta University, this study looked at five DNA-based epigenetic clocks to see how a daily multivitamin might influence healthy aging in healthy older adults.

    COSMOS represents the first and only reported, large-scale randomized controlled trial that examined the effect of a daily multivitamin and cocoa extract supplementation on biological aging using epigenetic clocks, which assess tiny changes in DNA that shift naturally as people age and can be used to estimate aging and age‑related risk patterns.

    Key Findings from the COSMOS Ancillary Study

    • Compared to the placebo-only group, people in the multivitamin group had slowing in all five epigenetic clocks, including statistically significant slowing seen in the two clocks that are predictive of mortality. Study authors state that the changes equated to about four months less biological aging over the course of two years.
    • Effects were stronger among participants who had accelerated biological aging at baseline, suggesting that individuals with higher biological age may derive greater benefit.
    • Authors note further research is needed to determine how changes in biological aging measures relate to long‑term health outcomes.

    Why This Matters

    • This COSMOS ancillary study offers new evidence that taking a daily multivitamin (Centrum Silver, which was used in the study) may help slow biological aging in older adults. This is the first reported evidence from a large-scale and long-term randomized controlled trial that a daily multivitamin is a safe, readily accessible, and low-cost intervention that may slow epigenetic aging.

    Ancillary Study Highlights

    • Participants: Nearly 1,000 older men aged ≥60 years and women aged ≥65 years, followed for two years.
    • Intervention: The study participants were randomized to take a daily multivitamin and cocoa extract; daily multivitamin and placebo; daily cocoa extract and placebo; or placebo-only.
    • Measures: Five epigenetic clocks used as DNA markers that act like "aging clocks," showing how fast or slow someone's body is aging at a cellular level on the inside.

    "These findings add to a growing body of evidence around multivitamin use and healthy aging," said Alpa V. Shah, Senior Director, Medical & Scientific Affairs, Haleon. "This COSMOS ancillary study provides new insight into how a daily multivitamin like Centrum Silver may relate to biological aging measures, complementing existing research on cognition and overall nutritional support."

    A Haleon brand, Centrum has been a long-time champion of nutrition research, a commitment that has made Centrum the most clinically studied multivitamin brand in the world. Backed by over 40 years of nutritional science, Centrum delivered on this legacy by providing Centrum Silver product, placebo, and packaging for the COcoa Supplement and Multivitamin Outcomes Study (COSMOS) trials and continues to support other nutrition and multivitamin research. This research reinforces the credibility, efficacy and scientific rigor that underpins Haleon's portfolio of trusted, science-backed brands.

    About Centrum

    Centrum has spent decades listening to the human body and learning what it needs to thrive. As the most clinically studied multivitamin brand in the world, Centrum continues its long-standing commitment to advancing nutritional science and supporting healthy aging. For more information about Centrum and Centrum Silver, visit Centrum.com.

    About Haleon US

    Haleon (NYSE:HLN) is a leading global consumer health company with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans six major categories: Oral Health, Pain Relief, Respiratory Health, Digestive Health, Wellness, and Sexual Wellness. Built on trusted science, innovation, and deep human understanding, Haleon's U.S. brands include Abreva, Advil, Benefiber, Centrum, Emergen-C, Eroxon, Excedrin, Flonase, Gas-X, Nexium, Nicorette, Parodontax, Polident, Preparation H, Pronamel, Sensodyne, Robitussin, Theraflu, TUMS, Voltaren, and more. For more information on Haleon and its brands, please visit www.haleon.com or contact USMediaRelations@haleon.com.

    Frequently Asked Questions (FAQ)

    What is biological aging, and why does it matter?

    • Biological aging reflects how well the body is functioning, which can differ from chronological age.
    • It can be measured with biomarkers such as DNA methylation–based epigenetic clocks, which are an evolving scientific tool.

    What is Centrum Silver?

    • Centrum Silver is a daily multivitamin formulated for adults 50+ and is the most clinically studied multivitamin brand in the world, having been included in, among other trials, in the main COSMOS trial and multiple ancillary analyses of the COSMOS trial.

    What did this COSMOS ancillary study find?

    • Compared to the placebo-only group, people in the multivitamin group had slowing in all five epigenetic clocks, including statistically significant slowing seen in the two clocks that are predictive of mortality. Study authors state that the changes equated to about four months less biological aging over the course of two years. Additionally, people who were biologically older than their actual age at the start of the trial benefited more.
    • In the COSMOS trial, participants were randomized to receive a daily multivitamin, cocoa extract, both interventions, or placebo. The slowing in biological aging observed in this ancillary analysis was seen in the multivitamin group compared to placebo. The findings reported in this analysis are specific to the multivitamin intervention.

    Can Centrum Silver help slow biological aging?

    • Yes. The results from this new analysis suggest that Centrum Silver may slow biological aging.

    What are epigenetic clocks?

    • Epigenetic clocks are biomarkers based on DNA methylation patterns that estimate biological aging. They are an emerging tool and not a diagnostic measure.

    Who conducted the research?

    • The ancillary study was led by independent academic researchers at Mass General Brigham and Augusta University as part of the broader COSMOS program.

    Was Centrum involved in the study?

    • Yes. These independent academic researchers used Centrum Silver as the daily multivitamin tested in the ancillary study.

    Where can I read the study?

    • The full Nature Medicine study can be found at https://www.nature.com/articles/s41591-026-04239-3.

    These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20260309182881/en/

    MEDIA CONTACT

    Ellie Carone

    Ellie.Carone@edelman.com

    Get the next $HLN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HLN

    DatePrice TargetRatingAnalyst
    1/23/2026Equal Weight → Overweight
    Barclays
    9/16/2025Overweight → Equal Weight
    Barclays
    9/10/2025Neutral → Buy
    Goldman
    5/27/2025$13.40Neutral → Outperform
    BNP Paribas Exane
    5/9/2025$11.25Equal-Weight → Overweight
    Morgan Stanley
    3/5/2025Buy → Hold
    HSBC Securities
    1/10/2025Overweight → Equal-Weight
    Morgan Stanley
    1/8/2025Outperform → Mkt Perform
    Bernstein
    More analyst ratings

    $HLN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    One in Three Western Consumers Now Buy Products Discovered on Social Platforms as AI Reshapes Commerce, According to NIQ

    New insights presented at The Consumer Goods Forum Global Summit highlight how AI is accelerating the convergence of global commerce models—reshaping growth strategies for brands and retailers NIQ (NYSE:NIQ), a leading consumer intelligence company, today revealed new analysis presented at The Consumer Goods Forum (CGF) Global Summit showing that nearly one in three consumers in Western markets now purchase products they first discover on social platforms, as artificial intelligence (AI) and emerging commerce models accelerate a shift toward discovery-led commerce. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626970024/en

    6/26/26 4:00:00 AM ET
    $NIQ
    $HLN
    Computer Software: Programming Data Processing
    Technology
    Package Goods/Cosmetics
    Consumer Discretionary

    Advil Challenges Sports Culture's "No Pain No Gain" Mentality This Summer

    The brand is launching Rewriting Pain, a new campaign and partnership with soccer legend Jozy Altidore to redefine what strength looks like Key Takeaways: Advil is launching Rewriting Pain, a new campaign challenging sports culture's "no pain no gain" mentality and redefining strength as confronting pain, not ignoring it. New research commissioned by Advil reveals 87% of current and former everyday athletes agree sports culture treats pain as a necessary part of success. Legendary U.S. Men's National Team forward and successful investor and entrepreneur, Jozy Altidore is partnering with Advil to encourage people to rethink outdated attitudes around pain, recovery and performance.

    6/9/26 7:00:00 AM ET
    $HLN
    Package Goods/Cosmetics
    Consumer Discretionary

    Haleon Invests in India to Deliver Better Everyday Health to Rural Communities

    £175m for first Haleon manufacturing site in Madhya Pradesh, central India Fast-growing India key to Haleon reaching one billion more consumers by 2030 India's consumer health market to reach over £23bn by 20301 Accelerated rural distribution to access 3 million outlets Affordable Sensodyne packs and investment to double ‘last-mile' reach in rural areas Haleon, a consumer company that is solely focused on better everyday health, today announces plans to expand its business in India, one of its fastest-growing markets and key to Haleon delivering its strategy and ambitions to reach one billion more consumers by 2030. Haleon will invest approximately £175 million2 in building

    6/8/26 5:11:00 AM ET
    $HLN
    Package Goods/Cosmetics
    Consumer Discretionary

    $HLN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Haleon plc upgraded by Barclays

    Barclays upgraded Haleon plc from Equal Weight to Overweight

    1/23/26 8:10:24 AM ET
    $HLN
    Package Goods/Cosmetics
    Consumer Discretionary

    Haleon plc downgraded by Barclays

    Barclays downgraded Haleon plc from Overweight to Equal Weight

    9/16/25 8:03:47 AM ET
    $HLN
    Package Goods/Cosmetics
    Consumer Discretionary

    Haleon plc upgraded by Goldman

    Goldman upgraded Haleon plc from Neutral to Buy

    9/10/25 7:56:26 AM ET
    $HLN
    Package Goods/Cosmetics
    Consumer Discretionary

    $HLN
    SEC Filings

    View All

    SEC Form 6-K filed by Haleon plc

    6-K - Haleon plc (0001900304) (Filer)

    6/22/26 6:42:49 AM ET
    $HLN
    Package Goods/Cosmetics
    Consumer Discretionary

    SEC Form 6-K filed by Haleon plc

    6-K - Haleon plc (0001900304) (Filer)

    6/15/26 6:04:47 AM ET
    $HLN
    Package Goods/Cosmetics
    Consumer Discretionary

    SEC Form 6-K filed by Haleon plc

    6-K - Haleon plc (0001900304) (Filer)

    6/8/26 3:59:21 PM ET
    $HLN
    Package Goods/Cosmetics
    Consumer Discretionary

    $HLN
    Leadership Updates

    Live Leadership Updates

    View All

    Haleon Appoints Richard Manso as US Chief Marketing Officer to Advance Data-driven, Consumer-centric Marketing in Delivering Better Everyday Health

    Today Haleon (NYSE:HLN), the consumer company that is solely focused on better everyday health, announced the appointment of Richard Manso as US Chief Marketing Officer, effective April 27, 2026. In this role, Manso will partner closely with CEO, US & President, North America Nathalie Gerschtein and the US leadership team to accelerate Haleon's evolution into a more agile, consumer-centric organization. Manso will lead Haleon's integrated US marketing organization, advancing how the company connects with consumers in the moments where health decisions actually happen. He will work across categories and global teams to integrate data, technology and human insight, strengthening Haleon's ab

    4/27/26 10:00:00 AM ET
    $HLN
    Package Goods/Cosmetics
    Consumer Discretionary

    HALEON APPOINTS CARL HANEY AS CHIEF R&D OFFICER

    LONDON, June 24, 2025 /PRNewswire/ -- Haleon (LSE: HLN) (NYSE:HLN) today announces the appointment of Carl Haney as Chief Research & Development Officer. Carl will join Haleon on 1 August 2025.  This appointment follows Franck Riot deciding to leave Haleon after six years in the business.  Carl joins Haleon from the Estée Lauder Companies Inc. where he has spent 13 years as Executive Vice President, Global Innovation and Research and Development. Carl previously spent over 20 years at P&G across Home, Health and Beauty Care.  Brian McNamara, Haleon's Chief Executive Officer commented: "I am delighted to welcome Carl to Haleon. Carl is a world-renowned leader in R&D, with significant experi

    6/24/25 8:00:00 AM ET
    $HLN
    Package Goods/Cosmetics
    Consumer Discretionary

    Haleon Welcomes Joe Sta-Romana as Chief Customer Officer to Lead US Growth and Transformation

    WARREN, N.J., Dec. 2, 2024 /PRNewswire/ -- Haleon, a world-leading consumer health company, is pleased to announce the appointment of Joe Sta-Romana as Chief Customer Officer (CCO) for its US business, effective December 1, 2024.  In this role, Joe will lead the organization's customer strategy, driving growth and transformation in the US market. Joe brings extensive leadership experience to the role, having spent over 20 years in the FMCG sector and serving in the military. Most recently Joe led Unilever's Walmart business, overseeing the company's largest US customer. In his

    12/2/24 7:53:00 AM ET
    $HLN
    Package Goods/Cosmetics
    Consumer Discretionary

    $HLN
    Financials

    Live finance-specific insights

    View All

    Yellow Wood Partners Portfolio Company Suave Brands Company Completes ChapStick Acquisition

    BOSTON, June 3, 2024 /PRNewswire/ -- Yellow Wood Partners LLC ("Yellow Wood"), a Boston-based private equity firm known for investing in consumer brands and companies, is pleased to announce that its portfolio company, Suave Brands Company, has successfully completed the acquisition of the ChapStick brand from Haleon (NYSE:HLN). This transaction also results in Haleon becoming a shareholder in Suave Brands Company. Suave Brands Company Chief Executive Officer, Daniel Alter, said, "As we continue to build Suave Brands Company as the top independent North American beauty & personal care company by combining the agility of a start-up with the power of market leading brands, the addition of Cha

    6/3/24 7:00:00 AM ET
    $HLN
    Package Goods/Cosmetics
    Consumer Discretionary

    Yellow Wood Partners Portfolio Company Suave Brands Company Acquires ChapStick from Haleon

    BOSTON, Jan. 25, 2024 /PRNewswire/ -- Yellow Wood Partners ("Yellow Wood"), a Boston-based private equity firm focused on investing in consumer brands and companies, today announced that its portfolio company Suave Brands Company has signed a binding offer to acquire the ChapStick brand from Haleon (NYSE:HLN), a global leader in consumer health. The transaction is intended to close in the first half of 2024 upon completion of customary closing and regulatory approvals. ChapStick invented the lip care category in the 1880s with the launch of a now-iconic lip balm that made ChapStick a household name. For more than a century, ChapStick has added products to its portfolio with innovative new i

    1/25/24 2:05:00 AM ET
    $HLN
    Package Goods/Cosmetics
    Consumer Discretionary

    Haleon plc Announces Expiration and Results of Exchange Offers for Certain Series of Notes Issued in Private Placements in Connection with the Separation from GSK

    Not for release, publication or distribution, directly or indirectly, in or into any jurisdiction into which such distribution would be unlawful. This notice is for informational purposes only and does not constitute an offer to purchase, or a solicitation of an offer to sell, any securities. The exchange offers referred to herein are being made solely pursuant to the Prospectus and related documents. The exchange offers referred to herein are not being made to holders of securities in any jurisdiction in which the making or acceptance thereof would not be in compliance with the securities, blue sky or other laws of such jurisdiction. LONDON, Oct. 31, 2022 /PRNewswire/ -- Haleon plc ("Haleon

    10/31/22 10:20:00 AM ET
    $HLN
    Package Goods/Cosmetics
    Consumer Discretionary

    $HLN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Haleon plc

    SC 13G - Haleon plc (0001900304) (Subject)

    11/13/24 1:20:28 PM ET
    $HLN
    Package Goods/Cosmetics
    Consumer Discretionary

    Amendment: SEC Form SC 13D/A filed by Haleon plc

    SC 13D/A - Haleon plc (0001900304) (Subject)

    10/3/24 6:59:16 PM ET
    $HLN
    Package Goods/Cosmetics
    Consumer Discretionary

    Amendment: SEC Form SC 13D/A filed by Haleon plc

    SC 13D/A - Haleon plc (0001900304) (Subject)

    10/1/24 7:38:46 PM ET
    $HLN
    Package Goods/Cosmetics
    Consumer Discretionary